Ocugen, Inc.

Ocugen, Inc. is a clinical-stage biopharmaceutical company headquartered in Malvern, Pennsylvania, focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines. Founded in 2013, the company's mission is to improve health and offer hope for patients across the globe, particularly those suffering from blindness diseases, by saving and restoring vision.

Ocugen's primary focus is on gene therapies for blindness diseases, leveraging a breakthrough modifier gene therapy platform that employs a gene-agnostic approach to potentially treat multiple gene mutations with a single product. Key pipeline candidates include OCU400 for retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA), OCU410 for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD), and OCU410ST for Stargardt disease. The company is also developing OCU200 for diabetic macular edema (DME), diabetic retinopathy (DR), and wet AMD. Beyond ophthalmology, Ocugen has a vaccine pipeline, including OCU500 (a COVID-19 vaccine candidate), and a cell therapy asset, NeoCart, for knee cartilage repair, held in its OrthoCellix subsidiary.

Under the leadership of Chairman, CEO, and Co-founder Shankar Musunuri, Ocugen is actively advancing its pipeline, with a strategic goal to file three Biologics License Applications (BLAs) within the next three years. In April 2026, the company completed dosing in its Phase 2/3 pivotal confirmatory trial for OCU410ST for Stargardt disease, with interim data expected mid-2026. OCU400 for retinitis pigmentosa is in a Phase 3 trial with enrollment completed, and a rolling BLA submission is planned to commence in Q3 2026. Additionally, positive preliminary 12-month data for OCU410 in geographic atrophy were announced in March 2026, showing a 46% lesion growth reduction. The company strengthened its financial position with a $22.5 million underwritten offering in January 2026.